JP2002520323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002520323A5 JP2002520323A5 JP2000559101A JP2000559101A JP2002520323A5 JP 2002520323 A5 JP2002520323 A5 JP 2002520323A5 JP 2000559101 A JP2000559101 A JP 2000559101A JP 2000559101 A JP2000559101 A JP 2000559101A JP 2002520323 A5 JP2002520323 A5 JP 2002520323A5
- Authority
- JP
- Japan
- Prior art keywords
- methylene
- phenylenebis
- composition
- aminomethyl
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 125000004122 cyclic group Chemical group 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 13
- 229920000768 polyamine Polymers 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- -1 1,4,8,11-tetraazacyclotetradecanyl Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000002184 metal Chemical class 0.000 claims 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 102000004274 CCR5 Receptors Human genes 0.000 claims 3
- 108010017088 CCR5 Receptors Proteins 0.000 claims 3
- 108010061299 CXCR4 Receptors Proteins 0.000 claims 3
- 102000012000 CXCR4 Receptors Human genes 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 claims 2
- PMGQWFFOFZQXSJ-UHFFFAOYSA-N 1-[4-(1,7-diazacyclotetradec-4-ylmethyl)phenyl]-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=C(CC2CCNCCCCCCCNCC2)C=CC=1CNCC1=CC=CC=N1 PMGQWFFOFZQXSJ-UHFFFAOYSA-N 0.000 claims 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- CWJJHESJXJQCJA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CC=N1 CWJJHESJXJQCJA-UHFFFAOYSA-N 0.000 claims 2
- TWTLJZJKDUYSON-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CN=C1 TWTLJZJKDUYSON-UHFFFAOYSA-N 0.000 claims 2
- RTHCDPLDSUOFCC-UHFFFAOYSA-N n-(pyridin-4-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=NC=CC=1CNCC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 RTHCDPLDSUOFCC-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- BOLSWSQFGOVHCQ-UHFFFAOYSA-N 1-[(2,6-dichloropyridin-4-yl)methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound ClC1=NC(Cl)=CC(CN2CCNCCCNCCNCCC2)=C1 BOLSWSQFGOVHCQ-UHFFFAOYSA-N 0.000 claims 1
- YRMKTQNDPSHONR-UHFFFAOYSA-N 1-phenyl-n-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]methanamine Chemical compound C=1C=CC=CC=1CNCC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 YRMKTQNDPSHONR-UHFFFAOYSA-N 0.000 claims 1
- UQJUPEBNPXJTGH-UHFFFAOYSA-N 2-[[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methylamino]methyl]aniline Chemical compound NC1=CC=CC=C1CNCC(C=C1)=CC=C1CN1CCNCCCNCCNCCC1 UQJUPEBNPXJTGH-UHFFFAOYSA-N 0.000 claims 1
- WRXILBMKDNKDQT-UHFFFAOYSA-N 4-[[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methylamino]methyl]aniline Chemical compound C1=CC(N)=CC=C1CNCC(C=C1)=CC=C1CN1CCNCCCNCCNCCC1 WRXILBMKDNKDQT-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- ZRMZSERGGSEOQR-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,7-triazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCNCCCCCCC2)C=CC=1CNCC1=CC=CC=N1 ZRMZSERGGSEOQR-UHFFFAOYSA-N 0.000 claims 1
- AVMFPLAFTONVSZ-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,7-triazacyclotetradec-4-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCCCCCNCC2)C=CC=1CNCC1=CC=CC=N1 AVMFPLAFTONVSZ-UHFFFAOYSA-N 0.000 claims 1
- JNHUKKWCWSUTLU-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(4,7,10,17-tetrazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-10-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCC=3C=CC=C(N=3)CCNCCNCC2)C=CC=1CNCC1=CC=CC=N1 JNHUKKWCWSUTLU-UHFFFAOYSA-N 0.000 claims 1
- NNODTJWTZJJMFX-UHFFFAOYSA-N n-[(5-methylpyrazin-2-yl)methyl]-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C1=NC(C)=CN=C1CNCC(C=C1)=CC=C1CN1CCNCCCNCCNCCC1 NNODTJWTZJJMFX-UHFFFAOYSA-N 0.000 claims 1
- VCGVGGOBDDNYPS-UHFFFAOYSA-N n-methyl-n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=CC=NC=1CN(C)CC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 VCGVGGOBDDNYPS-UHFFFAOYSA-N 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims 1
- 229960002169 plerixafor Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/111,895 | 1998-07-08 | ||
| US09/111,895 US6506770B1 (en) | 1996-06-06 | 1998-07-08 | Antiviral compounds |
| PCT/CA1999/000619 WO2000002870A1 (en) | 1998-07-08 | 1999-07-08 | Antiviral macrocyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002520323A JP2002520323A (ja) | 2002-07-09 |
| JP2002520323A5 true JP2002520323A5 (enExample) | 2005-09-15 |
| JP4637353B2 JP4637353B2 (ja) | 2011-02-23 |
Family
ID=22341015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000559101A Expired - Lifetime JP4637353B2 (ja) | 1998-07-08 | 1999-07-08 | 抗ウイルス性大環状化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US6506770B1 (enExample) |
| EP (1) | EP1095031B1 (enExample) |
| JP (1) | JP4637353B2 (enExample) |
| KR (1) | KR100778134B1 (enExample) |
| CN (2) | CN100339080C (enExample) |
| AP (1) | AP1436A (enExample) |
| AU (1) | AU767359B2 (enExample) |
| BR (1) | BR9912524A (enExample) |
| CA (1) | CA2336634C (enExample) |
| HU (1) | HUP0102930A3 (enExample) |
| IL (1) | IL140605A0 (enExample) |
| MX (1) | MXPA01000137A (enExample) |
| NO (1) | NO20010047L (enExample) |
| NZ (1) | NZ509699A (enExample) |
| PL (1) | PL345516A1 (enExample) |
| TR (1) | TR200100030T2 (enExample) |
| WO (1) | WO2000002870A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US20050085555A1 (en) * | 1997-08-21 | 2005-04-21 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| WO2001044229A1 (en) | 1999-12-17 | 2001-06-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| WO2002022599A2 (en) * | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| RU2277092C2 (ru) * | 2000-09-15 | 2006-05-27 | Анормед, Инк. | Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5 |
| US7052676B2 (en) * | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
| DK2371361T3 (da) * | 2001-07-31 | 2019-08-19 | Genzyme Corp | Fremgangsmåder til mobilisering af progenitor-/stamceller |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| IL161784A0 (en) * | 2001-12-21 | 2005-11-20 | Anormed Inc | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US20030199464A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
| EP1608352B1 (en) * | 2003-04-02 | 2009-12-30 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
| EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| EP1615633B1 (en) | 2003-04-22 | 2012-08-15 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7501518B2 (en) | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| JPWO2005051927A1 (ja) * | 2003-11-26 | 2007-12-06 | 株式会社クレハ | Ｈｉｖ−１感染末梢血単核球の刺激培養によるｃｄ４陽性ｔ細胞の培養方法、及びｈｉｖ−１の増殖阻害剤 |
| BRPI0514343A (pt) * | 2004-08-13 | 2008-06-10 | Anormed Inc | combinações de quimiocinas para mobilizar células progenitoras/tronco |
| US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
| US7825088B2 (en) * | 2005-04-25 | 2010-11-02 | The Cbr Institute For Biomedical Research, Inc. | Methods for the treatment of multiple myeloma |
| US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
| CA2619828A1 (en) * | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
| US20090035318A1 (en) * | 2005-09-29 | 2009-02-05 | British Columbia Cancer Agency Branch | Method and composition for increasing the engraftment efficiency of stem cells |
| BRPI0707446A2 (pt) | 2006-02-02 | 2011-05-03 | Allergan Inc | composições e métodos para o tratamento de doença oftálmica |
| US20090247570A1 (en) * | 2006-06-12 | 2009-10-01 | Pfizer Inc | Pharmaceuticals |
| MX2009001272A (es) * | 2006-08-02 | 2009-02-11 | Genzyme Corp | Terapia de combinacion. |
| BRPI0715393A2 (pt) * | 2006-08-07 | 2013-06-25 | Genzyme Corp | terapia de combinaÇço |
| US20090274687A1 (en) * | 2008-05-02 | 2009-11-05 | University Of Miami | Attenuation of hypoxia induced cardiovascular disorders |
| JP2012516354A (ja) * | 2009-01-30 | 2012-07-19 | ジェンザイム・コーポレーション | 乳癌を治療するための方法及び組成物 |
| CA2760292A1 (en) * | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
| WO2012037034A1 (en) | 2010-09-14 | 2012-03-22 | Glycomimetics, Inc. | E-selectin antagonists |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| WO2012061662A1 (en) * | 2010-11-03 | 2012-05-10 | Glycomimetics, Inc. | Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors |
| EP2709991B1 (en) | 2011-05-16 | 2020-09-02 | Genzyme Corporation | Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia |
| CN103159690B (zh) * | 2011-12-14 | 2015-03-25 | 朱靖华 | 对称大环胺化合物的结晶形式 |
| WO2013096926A1 (en) | 2011-12-22 | 2013-06-27 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
| PT2928476T (pt) | 2012-12-07 | 2018-05-10 | Glycomimetics Inc | Compostos, composições e métodos que utilizam antagonistas de e-selectina para mobilização de células hematopoiéticas |
| CN103058998B (zh) * | 2013-01-16 | 2016-04-13 | 山东鲁北药业有限公司 | 一种amd3465的制备工艺 |
| WO2016089872A1 (en) | 2014-12-03 | 2016-06-09 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
| PL3277284T3 (pl) | 2015-04-02 | 2021-03-08 | Proximagen, Llc | Nowe terapie nowotworu |
| WO2017011517A1 (en) | 2015-07-16 | 2017-01-19 | Emory University | Bis-amines, compositions, and uses related to cxcr4 inhibition |
| CA3000844A1 (en) * | 2015-10-19 | 2017-04-27 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating neurodegenerative diseases |
| US10953003B2 (en) | 2015-12-14 | 2021-03-23 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3389652B1 (en) | 2015-12-14 | 2022-09-28 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2935834T3 (es) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Métodos para tratar enfermedad de inmunodeficiencia |
| US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US11433048B2 (en) | 2016-06-16 | 2022-09-06 | Centre National De La Recherche Scientifique | CXCR4 receptor-binding compounds useful for increasing interferon level |
| CN109562106B (zh) | 2016-06-21 | 2023-03-21 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| JP2019524791A (ja) | 2016-08-08 | 2019-09-05 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ |
| US11072625B2 (en) | 2016-10-07 | 2021-07-27 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
| CA3054605A1 (en) | 2017-03-15 | 2018-09-20 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| CN111542597A (zh) | 2017-10-31 | 2020-08-14 | 美真达治疗公司 | 用于扩增造血干细胞和祖细胞的组合物和方法 |
| JP2021503008A (ja) | 2017-10-31 | 2021-02-04 | マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 造血幹細胞および前駆細胞移植療法のための組成物および方法 |
| US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| US10058573B1 (en) | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
| WO2019113375A2 (en) | 2017-12-06 | 2019-06-13 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| BR112020013198A2 (pt) | 2017-12-29 | 2020-12-01 | Glycomimetics, Inc. | inibidores heterobifuncionais de e-selectina e galectina-3 |
| CN109988153B (zh) * | 2017-12-29 | 2021-11-19 | 深圳夏浠湾医药科技有限公司 | 一种川芎嗪衍生物及其制备方法和应用 |
| US20200338132A1 (en) | 2018-01-03 | 2020-10-29 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| KR20200128025A (ko) | 2018-03-05 | 2020-11-11 | 글리코미메틱스, 인크. | 급성 골수성 백혈병 및 관련 병태의 치료 방법 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020139962A1 (en) | 2018-12-27 | 2020-07-02 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
| WO2021087406A1 (en) | 2019-11-01 | 2021-05-06 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
| AU2021263754A1 (en) | 2020-04-27 | 2022-12-01 | Ensoma, Inc. | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
| EP4308694A1 (en) | 2021-03-16 | 2024-01-24 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9105489D0 (en) | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) * | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| WO1999047158A2 (en) | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| EP1072273B1 (en) | 1998-03-24 | 2006-07-26 | Chugai Seiyaku Kabushiki Kaisha | Vascularization inhibitors |
| WO1999065507A1 (en) | 1998-06-19 | 1999-12-23 | The General Hospital Corporation | Modulating platelet function |
| WO2000006086A2 (en) * | 1998-07-31 | 2000-02-10 | The Trustees Of Columbia University In The City Of New York | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| WO2005002522A2 (en) * | 2003-06-30 | 2005-01-13 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for treating tissue ischemia |
| US7315917B2 (en) * | 2005-01-20 | 2008-01-01 | Sandisk Corporation | Scheduling of housekeeping operations in flash memory systems |
-
1998
- 1998-07-08 US US09/111,895 patent/US6506770B1/en not_active Expired - Lifetime
-
1999
- 1999-07-08 WO PCT/CA1999/000619 patent/WO2000002870A1/en not_active Ceased
- 1999-07-08 HU HU0102930A patent/HUP0102930A3/hu unknown
- 1999-07-08 BR BR9912524-2A patent/BR9912524A/pt not_active Application Discontinuation
- 1999-07-08 EP EP99928956.4A patent/EP1095031B1/en not_active Expired - Lifetime
- 1999-07-08 NZ NZ509699A patent/NZ509699A/en not_active IP Right Cessation
- 1999-07-08 TR TR2001/00030T patent/TR200100030T2/xx unknown
- 1999-07-08 CN CNB2005100094866A patent/CN100339080C/zh not_active Expired - Lifetime
- 1999-07-08 PL PL99345516A patent/PL345516A1/xx not_active Application Discontinuation
- 1999-07-08 MX MXPA01000137A patent/MXPA01000137A/es active IP Right Grant
- 1999-07-08 KR KR1020017000220A patent/KR100778134B1/ko not_active Expired - Fee Related
- 1999-07-08 AP APAP/P/2001/002043A patent/AP1436A/en active
- 1999-07-08 CA CA002336634A patent/CA2336634C/en not_active Expired - Fee Related
- 1999-07-08 JP JP2000559101A patent/JP4637353B2/ja not_active Expired - Lifetime
- 1999-07-08 AU AU45959/99A patent/AU767359B2/en not_active Expired
- 1999-07-08 CN CNB998082600A patent/CN1195745C/zh not_active Expired - Fee Related
- 1999-07-08 IL IL14060599A patent/IL140605A0/xx unknown
- 1999-07-08 US US09/743,561 patent/US6872714B1/en not_active Expired - Lifetime
-
2001
- 2001-01-04 NO NO20010047A patent/NO20010047L/no not_active Application Discontinuation
-
2002
- 2002-05-09 US US10/143,692 patent/US6756391B2/en not_active Expired - Lifetime
-
2004
- 2004-06-21 US US10/872,735 patent/US7160872B2/en not_active Expired - Fee Related
- 2004-11-17 US US10/991,944 patent/US7414065B2/en not_active Expired - Fee Related
-
2008
- 2008-07-29 US US12/182,044 patent/US7709486B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002520323A5 (enExample) | ||
| JP4913724B2 (ja) | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）の阻害剤としての置換されたピリドン | |
| US6232327B1 (en) | Indolyl-3-glyoxylic acid derivatives having antitumor action | |
| ES2261476T3 (es) | Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa. | |
| JP2002536329A5 (enExample) | ||
| JP2005530722A5 (enExample) | ||
| FI90980B (fi) | Menetelmä N-heterosyklisten N-(4-piperidyyli)-amidien valmistamiseksi | |
| ES2239596T3 (es) | Compuestos de pirazol sustituidos. | |
| NZ601794A (en) | Di - substituted pyridine derivatives as anticancers | |
| RU2002111344A (ru) | Хинуклидиновое соединение и лекарственный препарат, содержащий данное соединение в качестве активного ингредиента | |
| JP2010513304A5 (enExample) | ||
| JP2005536458A5 (enExample) | ||
| CN110894196A (zh) | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 | |
| JP2008510828A5 (enExample) | ||
| JPWO2003037862A1 (ja) | アミド誘導体及び医薬 | |
| JPWO2022173678A5 (enExample) | ||
| JP2010529991A5 (enExample) | ||
| CA2585053A1 (en) | Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors | |
| KR100510854B1 (ko) | 혈전성질환의치료를위한피롤리딘,피페리딘및헥사하이드로아제핀의카르복사미드유도체 | |
| CA2104794A1 (en) | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | |
| JP2002523511A5 (enExample) | ||
| AU2020314910A1 (en) | Aurora kinase inhibitor and use thereof | |
| MY125295A (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives | |
| CA2080127A1 (en) | Pyridines as medicaments | |
| JP2003221386A5 (enExample) |